PharmaCyte Biotech, Inc.
PMCB
$1.04
$0.032.97%
NASDAQ
07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 13.44M | 15.54M | 16.76M | 20.84M | 32.64M |
Total Receivables | 4.61M | 3.70M | -- | -- | -- |
Inventory | -- | -- | -- | -- | -- |
Prepaid Expenses | 238.20K | 223.80K | 207.40K | 493.20K | 240.20K |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | 820.00K | 2.92M | -- | -- | -- |
Total Current Assets | 19.11M | 22.38M | 16.96M | 21.33M | 32.88M |
|
|||||
Total Current Assets | 19.11M | 22.38M | 16.96M | 21.33M | 32.88M |
Net Property, Plant & Equipment | -- | -- | -- | -- | -- |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | 1.55M | 1.55M | 1.55M | 1.55M | 1.55M |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 4.82M | 8.77M | 6.69M | 7.36M | 6.65M |
Total Assets | 45.11M | 55.17M | 43.83M | 55.10M | 70.19M |
|
|||||
Total Accounts Payable | 465.20K | 399.20K | 484.90K | 348.60K | 554.00K |
Total Accrued Expenses | 345.70K | 521.10K | 709.40K | 707.20K | 684.10K |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Liabilities | 250.00K | 1.99M | -- | 3.72M | 6.23M |
Total Other Current Liabilities | 250.00K | 1.99M | -- | 3.72M | 6.23M |
Total Current Liabilities | 1.06M | 2.91M | 1.19M | 4.78M | 7.47M |
|
|||||
Total Current Liabilities | 1.06M | 2.91M | 1.19M | 4.78M | 7.47M |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | 458.00K | 363.00K | 2.38M | 6.87M | 9.68M |
Total Liabilities | 1.52M | 3.28M | 3.58M | 11.65M | 17.15M |
|
|||||
Common Stock & APIC | 181.55M | 181.49M | 181.43M | 181.36M | 182.73M |
Retained Earnings | -93.33M | -84.97M | -96.72M | -93.67M | -92.20M |
Treasury Stock & Other | -44.63M | -44.63M | -44.46M | -44.23M | -42.81M |
Total Common Equity | 43.59M | 51.89M | 40.25M | 43.45M | 47.71M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | 5.33M |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | 5.33M |
|
|||||
Total Common Equity | 43.59M | 51.89M | 40.25M | 43.45M | 47.71M |
Total Preferred Equity | -- | -- | -- | -- | 5.33M |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 43.59M | 51.89M | 40.25M | 43.45M | 53.04M |
|